Lacidipine Doc Generici (Lacidipine)

Lacidipine is a dihydropyridine calcium channel blocker used to manage high blood pressure and related cardiovascular conditions.

• Hypertension: lowers both systolic and diastolic blood pressure, helping to achieve target levels in patients with primary hypertension.
• Essential hypertension: provides sustained blood pressure control as part of combination therapy for patients requiring long‑term management.
• Isolated systolic hypertension: effectively reduces elevated systolic pressure in older adults where diastolic values remain normal.

• Lacidipine selectively inhibits L-type calcium channels in vascular smooth muscle cells. By blocking calcium influx, it prevents contraction of the arterial wall, causing vasodilation. The resulting decrease in peripheral vascular resistance leads to a reduction in systolic and diastolic blood pressure, aiding control of hypertension.

Lacidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate pain often occurring after dose initiation.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Tachycardia: increased heart rate without accompanying symptoms.
• Nausea: mild stomach discomfort or urge to vomit.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention.
• Myocardial infarction: rare occurrence of heart attack symptoms.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Severe allergic reaction: rash, itching, or anaphylaxis.
• Neutropenia: significant reduction in white blood cells.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use caution and consider dose adjustment in patients with liver disease.
• Concomitant antihypertensives: evaluate for additive blood‑pressure‑lowering effects.
• Heart failure: monitor for signs of fluid overload or worsening symptoms.
• Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Nitrates: combined use may cause profound hypotension.
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lacidipine plasma levels, raising risk of adverse effects.
• Grapefruit juice: can markedly elevate drug concentrations.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (beta‑blockers, ACE inhibitors, diuretics): may enhance blood‑pressure‑lowering effect.

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lacidipine effectiveness.
• Antidiabetic agents: monitor glucose control as blood‑pressure changes can affect glycemic levels.